1 |
Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Talalay P. 2005. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. U. S. A. 102:4584-4589.
DOI
|
2 |
Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG Jr, Suh N, Wang Y, Gribble GW. 2000. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43:4233-4246.
DOI
|
3 |
Jeon R and Rho GJ. 2020. Porcine somatic cell nuclear transfer using telomerase reverse transcriptase-transfected mesenchymal stem cells reduces apoptosis induced by replicative senescence. J. Anim. Reprod. Biotechnol. 35:215-222.
DOI
|
4 |
Lee HJ, Park BJ, Jeon RH, Jang SJ, Son YB, Lee SL, Rho GJ, Lee WJ. 2019. Alteration of apoptosis during differentiation in human dental pulp-derived mesenchymal stem cell. J. Anim. Reprod. Biotechnol. 34:2-9.
DOI
|
5 |
Kim JE, Park H, Choi SH, Kang TC. 2019. CDDO-Me selectively attenuates CA1 neuronal death induced by status epilepticus via facilitating mitochondrial fission independent of LONP1. Cells 8:833.
DOI
|
6 |
Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Kensler TW. 2007. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther. 6:154-162.
DOI
|
7 |
Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Dezube BJ. 2012. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18:3396-3406.
DOI
|
8 |
Wang YY, Yang YX, Zhe H, Zhou SF. 2014. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des. Devel. Ther. 8:2075-2088.
|
9 |
Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, Ferguson DA, Grossman E, Chen J, Zhou XJ, Hartono J, Winterberg P, Chen B, Lu CY. 2011. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. Am. J. Physiol. Renal Physiol. 300:F1180-F1192.
DOI
|
10 |
Xia H, Li X, Gao W, Fu X, Fang RH, Zhang K. 2018. Tissue repair and regeneration with endogenous stem cells. Nat. Rev. Mater. 3:174-193.
DOI
|
11 |
Holan V, Hermankova B, Bohacova P, Kossl J, Chudickova M, Hajkova M, Krulova M, Javorkova E. 2016. Distinct immunoregulatory mechanisms in mesenchymal stem cells: role of the cytokine environment. Stem Cell Rev. Rep. 12:654-663.
DOI
|
12 |
Leyendecker A Jr, Pinheiro CCG, Bueno DF. 2018. The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review. Front. Immunol. 9:2056.
DOI
|
13 |
Loboda A, Damulewicz M, Pyza E, Dulak J. 2016. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell. Mol. Life Sci. 73:3221-3247.
DOI
|
14 |
Li Z, Zhong JF. 2019. Mesenchymal stem cells: characteristics, function, and application. Stem Cells Int. 2019:8106818.
|
15 |
Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn MB. 2007. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 67:2414-2419.
DOI
|
16 |
Livak KJ and Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
DOI
|
17 |
Lohan P, Treacy O, Griffin MD, Ryan AE. 2017. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning? Front. Immunol. 8:1626.
DOI
|
18 |
Ocansey DKW, Pei B, Yan Y, Qian H, Zhang X, Mao F. 2020. Improved therapeutics of modified mesenchymal stem cells: an update. J. Transl. Med. 18:42.
DOI
|
19 |
Ruiz S, Pergola PE, Vaziri ND. 2013. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83:1029-1041.
DOI
|
20 |
Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Warnock DG; BEAM Study Investigators. 2011. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365:327-336.
DOI
|
21 |
Alam J, Stewart D, Touchard C, Boinapally S, Cook JL. 1999. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274:26071-26078.
DOI
|
22 |
Moon SW, Lee HJ, Lee WJ, Lee SL. 2018. Trans-differentiation induction of human-mesenchymal stem cells derived from different tissue origin and evaluation of their potential for differentiation into corneal epithelial-like cells. J. Emb. Trans. 33:85-97.
DOI
|
23 |
Fitzsimmons REB, Mazurek MS, Simmons CA. 2018. Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. Stem Cells Int. 2018:8031718.
|
24 |
Jo JH, Kim TM. 2019. The potential of renal progenitor cells in kidney diseases: preclinical findings. J. Anim. Reprod. Biotechnol. 34:70-74.
DOI
|
25 |
Noronha NC, Mizukami A, Caliari-Oliveira C, Cominal JG, Rocha JLM, Covas DT, Malmegrim KCR. 2019. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res. Ther. 10:131.
DOI
|
26 |
Ahmad R, Raina D, Meyer C, Kufe D. 2006. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J. Biol. Chem. 281:35764-35769.
DOI
|
27 |
Borella R, Forti L, Gibellini L, De Gaetano A, De Biasi S, Nasi M, Pinti M. 2019. Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids. Molecules 24:4097.
DOI
|